

THE SILENT THEAT OF HUMAN METAPNEUMOVIRUS: CLINICAL CHALLENGES AND ADVANCES IN DIAGNOSTIC APPROACHES

Sachin Harshvardhan Bhaware^{*1}, Viraj Vinayak Naravane^{*2},
Sachin Kumar^{*3}, Utkarsh Sharma^{*4}, Zulekha Yasmeen Mohammed Abdul Muqeen^{*5}

^{*1}Shri. Sambhaji College Of Pharmacy, Khadkut, Nanded.

^{*2}College Of Pharmacy (Poly), Sawarde

^{*3}Central University Of Haryana.

^{*4}United Institute Of Pharmacy, Naini, Prayagraj.

^{*5}Kishori College Of Pharmacy, Beed.

ABSTRACT

Human Metapneumovirus (HMPV) is an important respiratory pathogen that causes a wide spectrum of diseases, ranging from mild upper respiratory infections to severe pneumonia and bronchiolitis, particularly in children, the elderly, and immunocompromised individuals. Despite its clinical relevance, HMPV remains under-recognized, as its symptoms often overlap with other respiratory viruses such as RSV, influenza, and human rhinovirus. The challenges in diagnosing HMPV are compounded by the lack of specific antiviral treatments and the frequent occurrence of co-infections with other pathogens. Conventional diagnostic approaches, including viral culture and serology, have been largely replaced by molecular techniques, with reverse transcription-polymerase chain reaction (RT-PCR) emerging as the gold standard. Advances in diagnostic methodologies, including next-generation sequencing (NGS), multiplex PCR, and rapid antigen tests, are improving the accuracy and speed of detection, enabling better clinical management of HMPV infections. However, further research is needed to develop targeted antiviral therapies and effective vaccines. This review highlights the clinical challenges associated with HMPV infections and discusses recent advancements in diagnostic technologies, aiming to inform future strategies for improving patient outcomes.

1. INTRODUCTION

Human Metapneumovirus (HMPV)

Human Metapneumovirus (HMPV) is a respiratory pathogen that was first identified in 2001 by researchers who isolated the virus from children with respiratory illnesses. It belongs to the Paramyxoviridae family, in the Metapneumovirus genus, which also includes viruses like Respiratory Syncytial Virus (RSV) and Human Pneumovirus (HPV). HMPV shares several similarities with these viruses, particularly in its ability to cause respiratory infections ranging from mild upper respiratory tract illness to severe lower respiratory tract diseases, such as pneumonia and bronchiolitis.

Role in Respiratory Infections

HMPV plays a significant role in the etiology of respiratory infections, particularly in high-risk groups such as:

- **Children under 5 years:** HMPV is one of the leading causes of acute respiratory infections in young children, often manifesting as wheezing, bronchiolitis, and pneumonia.
- **The elderly:** Older adults, especially those with underlying health conditions like heart disease or chronic obstructive pulmonary disease (COPD), are at higher risk for severe HMPV infections.
- **Immunocompromised patients:** Individuals with weakened immune systems, including those undergoing chemotherapy or organ transplantation, are vulnerable to more severe infections and complications due to HMPV.

These groups often experience more severe and prolonged symptoms, and hospitalizations due to HMPV infections are common, especially during seasonal outbreaks. HMPV is also associated with substantial morbidity and mortality, particularly in immunocompromised patients.

Global Prevalence of HMPV Infections

HMPV infections are prevalent worldwide, with documented cases occurring year-round, although seasonal peaks are observed, particularly in temperate regions during the colder months (typically winter to early spring). In tropical regions, however, HMPV may circulate throughout the year, complicating its epidemiological pattern. HMPV is responsible for a considerable proportion of respiratory infections in both children and adults. While exact prevalence rates vary by region, studies suggest that HMPV accounts for a significant number of hospitalizations due to respiratory illness in vulnerable populations.

Similarity to Other Respiratory Viruses

HMPV shares several characteristics with other common respiratory viruses, such as:

- **Respiratory Syncytial Virus (RSV):** Both HMPV and RSV cause similar clinical presentations, including wheezing, bronchiolitis, and pneumonia, particularly in infants and young children. The two viruses are often indistinguishable in terms of symptoms, which can complicate diagnosis without laboratory testing.
- **Influenza:** Like influenza, HMPV can lead to seasonal outbreaks and has similar respiratory manifestations, including fever, cough, and difficulty breathing. Both viruses can lead to severe disease in high-risk individuals, although influenza may have a broader spectrum of symptoms affecting other systems in the body.

Despite these similarities, HMPV tends to be less studied compared to RSV and influenza, which has contributed to a relative underestimation of its clinical impact and a lack of specific antiviral treatments. However, as research into HMPV increases, a better understanding of its role in respiratory infections continues to emerge, highlighting its importance as a global health concern.

2. CLINICAL CHALLENGES

Human Metapneumovirus (HMPV) poses several clinical challenges due to its broad disease spectrum, potential for co-infection, lack of specific antiviral treatments, and its impact on vulnerable populations. These challenges make the management and diagnosis of HMPV infections more complex and highlight the need for improved diagnostic tools and therapeutic strategies.

Symptoms & Disease Spectrum

HMPV can cause a wide range of respiratory illnesses, varying from mild upper respiratory tract infections (URIs) to severe lower respiratory tract infections (LRTIs). The symptoms often resemble those of other respiratory viruses, which can make it difficult to distinguish HMPV from infections caused by viruses like RSV, influenza, or rhinovirus.

- **Mild cases:** In some individuals, particularly in healthy children and adults, HMPV may present as a mild cold or upper respiratory infection with symptoms such as a runny nose, sore throat, cough, and low-grade fever.
- **Severe cases:** In more severe infections, HMPV can cause bronchiolitis, bronchitis, and pneumonia, particularly in vulnerable populations. The infection may present with more serious symptoms, including wheezing, difficulty breathing, and hypoxia, requiring hospitalization or intensive care.

Because HMPV's clinical presentation overlaps with many other respiratory viruses, clinicians must rely on laboratory tests to confirm the diagnosis. This often involves using PCR-based methods to differentiate between HMPV and other respiratory pathogens, a process that can be time-consuming and requires access to specialized diagnostic tools.

Viral Co-Infections

One of the significant challenges in diagnosing and managing HMPV infections is its frequent co-infection with other respiratory viruses. Co-infections are common in patients with respiratory illnesses, especially in children, the elderly, and those with weakened immune systems.

- **Common co-infecting viruses:** HMPV is often detected alongside viruses like RSV, influenza, human rhinovirus, or adenovirus. These co-infections can complicate both diagnosis and treatment because the symptoms may be more severe and can mimic other viral infections, leading to diagnostic uncertainty.
- **Impact of co-infection:** Co-infections can lead to more severe clinical outcomes, including prolonged hospital stays, increased likelihood of requiring ventilatory support, and higher mortality rates. Moreover, co-infections can make it more challenging to pinpoint the most appropriate treatment strategy and to understand the disease course.

This makes it essential for clinicians to conduct thorough diagnostic workups that include testing for multiple pathogens when respiratory illness is suspected, particularly in high-risk individuals.

Lack of Specific Antiviral Therapies

Currently, there are no specific antiviral therapies approved for the treatment of HMPV infections. Management remains primarily supportive, focusing on alleviating symptoms and preventing complications. Supportive care typically includes:

- Oxygen therapy for patients with severe respiratory distress
- Bronchodilators and corticosteroids for patients with wheezing or bronchospasm
- Hydration and fever management

While supportive care can be effective in improving outcomes for many patients, the absence of targeted antiviral therapies means that treatment remains limited. There is ongoing research into the development of antiviral drugs and

monoclonal antibodies that could specifically target HMPV, but as of now, these potential therapies are still in the experimental stages.

Risk Groups

HMPV is associated with more severe disease in certain high-risk populations. These groups are more susceptible to the complications of HMPV infections, including pneumonia, respiratory failure, and prolonged illness:

- **Children under 5 years:** This age group is particularly vulnerable to severe HMPV infections, especially infants. Infants under the age of 1 are at higher risk for developing bronchiolitis and requiring hospitalization.
- **Elderly individuals:** Older adults, particularly those over 65, are at increased risk for developing severe disease due to age-related changes in immune function and the presence of chronic comorbidities such as heart disease, diabetes, or COPD.
- **Immunocompromised patients:** Individuals with compromised immune systems, such as those undergoing chemotherapy, organ transplant recipients, and HIV/AIDS patients, are more likely to experience prolonged or severe infections due to their weakened ability to fight off the virus.
- **Patients with underlying respiratory conditions:** Individuals with asthma, chronic obstructive pulmonary disease (COPD), or other chronic lung diseases are also at increased risk for more severe outcomes, as HMPV can exacerbate pre-existing respiratory conditions.

These high-risk groups require more intensive monitoring and care, and the lack of targeted therapies for HMPV makes managing these cases even more challenging. Therefore, early detection and proactive supportive treatment are critical in preventing severe outcomes in these populations.

3. DIAGNOSTIC APPROACHES

The diagnosis of Human Metapneumovirus (HMPV) infection has evolved significantly over the past two decades. While traditional methods remain important, advances in molecular diagnostics have led to more rapid, sensitive, and accurate ways to identify HMPV infections, particularly in resource-limited settings where timely diagnosis is critical. Below is an overview of both traditional and emerging diagnostic methods for HMPV:

Traditional Methods

- **Virus Isolation:**

Historically, HMPV was first identified through virus isolation in cell culture. This process involves inoculating patient samples, such as nasopharyngeal swabs or aspirates, onto cell cultures and observing the growth of the virus. Although virus isolation was crucial in the initial discovery of HMPV, it has significant limitations:

- **Time-consuming:** It can take several days (typically 3–7 days) for viral growth to become detectable, making this method impractical for acute clinical settings where quick results are needed.
- **Labor-intensive:** It requires specialized laboratory infrastructure and expertise, limiting its accessibility in some healthcare settings.
- **Low sensitivity:** Some viruses may not grow efficiently in culture, which can lead to false-negative results.

Due to these limitations, virus isolation has largely been replaced by more efficient methods, such as PCR.

- **Polymerase Chain Reaction (PCR):**

PCR, specifically Reverse Transcription-PCR (RT-PCR), has become the gold standard for diagnosing HMPV infections due to its high sensitivity, specificity, and ability to detect the virus in clinical samples like nasal swabs, throat swabs, or bronchoalveolar lavage fluid. RT-PCR offers several advantages:

- **High Sensitivity and Specificity:** PCR can detect even low viral loads in patient samples and is highly specific, minimizing the risk of false-positive results.
- **Rapid Results:** PCR results can typically be obtained within a few hours, making it a valuable tool in clinical practice, especially in hospital settings.
- **Detection of Subtypes:** PCR can differentiate between HMPV subtypes (A and B), which may have implications for disease severity or epidemiological tracking.

As a result, PCR has become the preferred diagnostic method for HMPV, especially when rapid and accurate detection is necessary.

Advances in Molecular Diagnostics

- **Next-Generation Sequencing (NGS):**

NGS technologies offer a powerful tool for diagnosing HMPV, particularly in challenging cases:

- **Detection in Co-Infected Samples:** NGS can detect HMPV even when co-infected with other respiratory viruses (e.g., RSV, influenza). This is especially important as co-infections are common in respiratory illness, and traditional PCR-based methods may not always provide clear results in such cases.
- **Genetic Profiling:** NGS provides detailed genetic information about the virus, which can help in tracking viral mutations, understanding viral evolution, and identifying potential epidemiological patterns.
- **Research Applications:** NGS is primarily used in research settings due to its complexity and cost but holds significant promise for improving the accuracy of diagnostics, particularly in cases of co-infection or atypical presentations.

- **Point-of-Care Testing:**

There is an increasing push toward the development of rapid, point-of-care (POC) diagnostic tests for HMPV that can be used at the bedside or in outpatient settings. These tests aim to provide quick results, enabling faster clinical decision-making. Some of the emerging technologies include:

- **Rapid Molecular Assays:** New PCR-based point-of-care devices have been developed that can deliver results within an hour. These devices are designed to be portable, user-friendly, and suitable for low-resource environments.
- **Diagnostic Devices:** Portable diagnostic platforms, such as isothermal amplification systems (e.g., LAMP), are being explored as alternatives to traditional PCR. These systems are typically more affordable and faster than conventional PCR.

While these rapid tests are promising, they may still face challenges related to sensitivity and specificity compared to traditional laboratory-based PCR tests.

- **Lateral Flow Assays (Immunological Tests):**

Lateral flow assays (LFAs), also known as rapid antigen tests, are simple and easy-to-use diagnostic tools that are often employed for the detection of viruses like HMPV in clinical settings. These tests detect specific viral proteins (antigens) in patient samples and provide results in about 15–30 minutes. Advantages and limitations include:

- **Advantages:** Fast, easy to administer, and inexpensive. These tests are particularly useful in low-resource or high-throughput environments (e.g., during outbreaks).
- **Limitations:** LFAs generally have lower sensitivity than PCR-based methods, meaning that they may miss infections in patients with low viral loads or early-stage disease. They are also more prone to false-negative results, which can affect the accuracy of diagnosis.

Nonetheless, LFAs are useful for providing quick presumptive diagnoses in a clinical context, particularly when PCR is not immediately available.

- **Serological Testing:**

Serological testing involves detecting antibodies in the blood to determine whether a person has been previously exposed to HMPV. While this approach is not typically used for diagnosing acute infections, it can play a role in epidemiological studies or in identifying past infections. The advantages and drawbacks of serological testing include:

- **Advantages:** Serological tests can provide information about the population's exposure to HMPV, helping to assess immunity levels and monitor infection trends. These tests are also useful for large-scale studies or surveillance programs.
- **Limitations:** Serological tests cannot be used to diagnose active infections as antibodies take time to develop, typically several days to weeks after exposure. Therefore, they are not ideal for diagnosing acute infections in clinical settings.

While serology can be useful in specific situations, it is not a routine diagnostic tool for identifying active HMPV infections, especially in the acute phase.

4. CURRENT AND FUTURE DIRECTIONS

- **Vaccine Development:** There is ongoing research into vaccines for HMPV, particularly for vulnerable populations.
- **Improved Diagnostics:** The future likely holds more efficient and accessible diagnostic tests, including multiplex PCR panels that can detect multiple respiratory pathogens at once.
- **Therapeutic Advances:** Investigating antiviral agents and monoclonal antibodies that could target HMPV.

5. CONCLUSION

- HMPV remains an important cause of respiratory illness, and clinical challenges include early diagnosis, differentiation from other respiratory viruses, and lack of specific treatments. Advances in diagnostic technologies and ongoing research into therapeutic and preventive strategies may improve outcomes in the future.

6. REFERENCES

- [1] Hasvold, J.; Sjoding, M.; Pohl, K.; Cooke, C.; Hyzy, R.C. The role of human metapneumovirus in the critically ill adult patient. *J. Crit. Care* 2016, 31, 233–237. [Google Scholar] [CrossRef] [PubMed]
- [2] Seki, M.; Yoshida, H.; Gotoh, K.; Hamada, N.; Motooka, D.; Nakamura, S.; Yamamoto, N.; Hamaguchi, S.; Akeeda, Y.; Watanabe, H.; et al. Severe respiratory failure due to co-infection with human metapneumovirus and *Streptococcus pneumoniae*. *Respir. Med. Case Rep.* 2014, 12, 13–15. [Google Scholar] [CrossRef]
- [3] Khan, A.; Khanna, V.; Majumdar, K. Demographics, Clinical Presentation and Outcome of Metapneumovirus Infection in Adults: A Case Series Analysis at Scarborough General Hospital, United Kingdom. *Cureus* 2024, 16, e73292. [Google Scholar] [CrossRef] [PubMed]
- [4] Philippot, Q.; Rammaert, B.; Dauriat, G.; Daubin, C.; Schlemmer, F.; Costantini, A.; Tandjaoui-Lambiotte, Y.; Neuville, M.; Desrochettes, E.; Ferre, A.; et al. Human metapneumovirus infection is associated with a substantial morbidity and mortality burden in adult inpatients. *Heliyon* 2024, 10, e33231. [Google Scholar] [CrossRef] [PubMed]
- [5] Miyakawa, R.; Zhang, H.; Brooks, W.A.; Prosperi, C.; Baggett, H.C.; Feikin, D.R.; Hammit, L.L.; Howie, S.R.C.; Kotloff, K.L.; Levine, O.S.; et al. Epidemiology of human metapneumovirus among children with severe or very severe pneumonia in high pneumonia burden settings: The Pneumonia Etiology Research for Child Health (PERCH) study experience. *Clin. Microbiol. Infect.* 2024. [Google Scholar] [CrossRef] [PubMed]
- [6] Kuang, L.; Xu, T.; Wang, C.; Xie, J.; Zhang, Y.; Guo, M.; Liang, Z.; Zhu, B. Changes in the epidemiological patterns of respiratory syncytial virus and human metapneumovirus infection among pediatric patients and their correlation with severe cases: A long-term retrospective study. *Front. Cell. Infect. Microbiol.* 2024, 14, 1435294. [Google Scholar] [CrossRef]
- [7] Walsh, E.E.; Peterson, D.R.; Falsey, A.R. Human metapneumovirus infections in adults: Another piece of the puzzle. *Arch. Intern. Med.* 2008, 168, 2489–2496. [Google Scholar] [CrossRef]
- [8] Contentin, L.; Guillon, A.; Garot, D.; Gaudy-Graffin, C.; Perrotin, D. Acute respiratory distress syndrome secondary to human metapneumovirus infection in a young healthy adult. *Intensive Care Med.* 2013, 39, 533–534. [Google Scholar] [CrossRef] [PubMed]
- [9] Haas, L.E.; Thijsen, S.F.; van Elden, L.; Heemstra, K.A. Human metapneumovirus in adults. *Viruses* 2013, 5, 87–110. [Google Scholar] [CrossRef] [PubMed]
- [10] Papenburg, J.; Alghounaim, M. Unraveling the Pneumonia Burden Associated With Human Metapneumovirus Infection. *Clin. Infect. Dis.* 2021, 72, 118–120. [Google Scholar] [CrossRef] [PubMed]
- [11] Falsey, A.R.; Erdman, D.; Anderson, L.J.; Walsh, E.E. Human metapneumovirus infections in young and elderly adults. *J. Infect. Dis.* 2003, 187, 785–790. [Google Scholar] [CrossRef] [PubMed]
- [12] Howard, L.M.; Edwards, K.M.; Zhu, Y.; Grijalva, C.G.; Self, W.H.; Jain, S.; Ampofo, K.; Pavia, A.T.; Arnold, S.R.; McCullers, J.A.; et al. Clinical Features of Human Metapneumovirus-Associated Community-acquired Pneumonia Hospitalizations. *Clin. Infect. Dis.* 2021, 72, 108–117. [Google Scholar] [CrossRef] [PubMed]
- [13] Li, I.W.; To, K.K.; Tang, B.S.; Chan, K.H.; Hui, C.K.; Cheng, V.C.; Yuen, K.Y. Human metapneumovirus infection in an immunocompetent adult presenting as mononucleosis-like illness. *J. Infect.* 2008, 56, 389–392. [Google Scholar] [CrossRef] [PubMed]
- [14] Nagasawa, M.; Udagawa, T.; Kato, T.; Tanaka, I.; Yamamoto, R.; Sakaguchi, H.; Sekikawa, Y. Observational Study on the Clinical Reality of Community-Acquired Respiratory Virus Infections in Adults and Older Individuals. *Pathogens* 2024, 13, 983. [Google Scholar] [CrossRef]
- [15] Vidaur, L.; Totorika, I.; Montes, M.; Vicente, D.; Rello, J.; Cilla, G. Human metapneumovirus as cause of severe community-acquired pneumonia in adults: Insights from a ten-year molecular and epidemiological analysis. *Ann. Intensive Care* 2019, 9, 86. [Google Scholar] [CrossRef]